Fusion Pharmaceuticals Inc (FUSN) has released an update.
Fusion Pharmaceuticals Inc. has announced a robust close to the year with its fourth quarter and full year financials for 2023, alongside updates on its clinical programs, particularly FPI-2265 for metastatic castration-resistant prostate cancer, with Phase 2/3 trials set to begin in Q2 2024. The company is also slated to present interim data at the AACR Annual Meeting in April. In addition, Fusion has begun production of clinical doses of FPI-2265 from its new GMP facility, bolstering its position in the radiopharmaceuticals market.
For further insights into FUSN stock, check out TipRanks’ Stock Analysis page.
